BofA analysts downgrade Inspire Medical on reimbursement coding concerns
BofA has downgraded Inspire Medical (NYSE:INSP) from "Neutral" to "Underperform" due to significant concerns regarding reimbursement coding for its Inspire V neuromodulation procedure. The company's prior guidance cut for 2026 and the continued lack of clarity on appropriate CPT coding, along with increasing competition and other market factors, led to the downgrade. Analysts do not foresee a sustainable improvement in the stock until a clear coding pathway is established, which is not expected until at least 2028.
Inspire Medical Systems Faces Coding Overhang, Estimate Risks, BofA Says
BofA Securities reiterated its Underperform rating and $130 price target on Inspire Medical Systems (NYSE: INSP), citing an overhang from the Centers for Medicare & Medicaid Services (CMS) new coding guidance for hypoglossal nerve stimulation effective July 1, 2024. The firm believes previous upside triggers, such as positive coverage and increased sleep specialist adoption, are now largely priced into the stock. They also noted that current consensus estimates appear aggressive, especially regarding patient diagnosis and implant rates for sleep-disordered breathing.
Insider Sell Alert: John Rondoni Sells Shares of Inspire Medical Systems Inc (INSP)
John Rondoni, an insider at Inspire Medical Systems Inc (INSP), sold 2,641 shares on May 15, 2026, reducing his total holdings to 27,165 shares. The company, focused on obstructive sleep apnea solutions, has seen nine insider sells and no buys over the past year. With a stock price of $43.28 and a GuruFocus Value of $219.65, the stock is identified as a "Possible Value Trap."
Officer at Inspire Medical (NYSE: INSP) sells 2,641 shares
John Rondoni, an officer at Inspire Medical Systems (NYSE: INSP), sold 2,641 shares of common stock in an open-market transaction on May 15, 2026, at a weighted average price of $43.28 per share. Following this sale, Rondoni directly holds 27,165 shares. This transaction, detailed in a Form 4 SEC filing, represents a net sale of $114,302 worth of shares.
Inspire Medical Systems (INSP) to report earnings tomorrow: Here is what to expect
This article announces that Inspire Medical Systems (INSP) is scheduled to report its earnings tomorrow. It suggests that investors should review the company's past performance and analyst estimates to anticipate the upcoming results. No financial figures or specific anticipations are provided within the given content.
Inspire Medical Systems (INSP) Is Down 9.5% After Cutting 2026 Outlook And Filing ESOP Shelf Registration - What's Changed
Inspire Medical Systems (INSP) recently reported a Q1 net loss and cut its 2026 revenue outlook to US$825M–US$875M, leading to a 9.5% stock drop. The company also filed an ESOP-related shelf registration and is phasing out its classified board structure. These changes, coupled with reimbursement and WISER program disruptions, signal near-term operational challenges and a shift in its investment narrative, emphasizing execution risk and potential long-run governance improvements.
Inspire Medical Systems (INSP) Is Down 9.5% After Cutting 2026 Outlook And Filing ESOP Shelf Registration - What's Changed
Inspire Medical Systems (INSP) recently reported a Q1 net loss and cut its 2026 revenue outlook to US$825 million–US$875 million, with diluted EPS of US$0.07–US$0.62. This downward revision, coupled with a shelf registration for ESOP-related shares and disruptions from reimbursement and the WISER program, highlights nearer-term operational pressures. The article suggests investors evaluate the impact of these changes on Inspire Medical Systems' investment narrative and risk profile, especially concerning its fair value and future growth prospects.
Inspire Medical Systems (INSP) Is Down 9.5% After Cutting 2026 Outlook And Filing ESOP Shelf Registration - What's Changed
Inspire Medical Systems (INSP) recently reported a Q1 net loss of US$11.29 million and cut its 2026 revenue outlook to US$825 million–US$875 million, causing its stock to drop 9.5%. The company also filed a US$118.82 million shelf registration for ESOP shares and is phasing out its classified board structure. These changes, coupled with reimbursement issues, highlight operational pressures and an effort to strengthen long-run governance, reshaping the investment narrative and risk profile for INSP.
Inspire Medical Systems (INSP) Earnings Date and Reports 2026 $INSP
Inspire Medical Systems (INSP) reported Q1 2026 earnings, beating analyst expectations with an EPS of $0.10 against an estimated -$0.28, and revenue of $204.58 million, exceeding estimates of $200.04 million. The company's earnings are projected to grow significantly by 76.92% in the next year, from $0.91 to $1.61 per share. Inspire Medical Systems' next earnings report is estimated for August 3, 2026, and the company has provided FY 2026 guidance for EPS between $0.750-$1.250 and revenue between $825.0-$875.0 million.
Inspire Medical Systems (INSP) price target decreased by 17.14% to 72.73
The article reports that the price target for Inspire Medical Systems (INSP) has been decreased by 17.14%, bringing it down to $72.73. This change indicates a significant reevaluation of the company's valuation by analysts.
[144] Inspire Medical Systems, Inc. SEC Filing
Inspire Medical Systems, Inc. (INSP) has filed a Form 144 illustrating the proposed resale of restricted common stock that vested under a registered plan. The filing details multiple vested lots of shares from earlier in the year and reports a recent sale of 700 shares by John Rondoni for $30,106.02 on May 14, 2026. Morgan Stanley Smith Barney LLC Executive Financial Services submitted this notice regarding the resale of these securities.
Inspire Medical (INSP) officer sells 700 shares at about $43
John Rondoni, an officer at Inspire Medical Systems, Inc. (INSP), reported an open-market sale of 700 shares of Common Stock. The shares were sold at a weighted average price of $43.01, with individual trades ranging from $43.00 to $43.03. Following this transaction, Rondoni directly owns 29,806 shares of the company.
Wellington Group reports 2.54M Inspire shares (INSP) representing 8.81% stake
Wellington Management Group LLP has filed an amended Schedule 13G/A, reporting beneficial ownership of 2,535,954 shares of Inspire Medical Systems, Inc. (INSP) common stock, which represents an 8.81% stake in the company. The filing indicates shared voting power over 2,473,739 shares and shared dispositive power over all 2,535,954 shares as of March 31, 2026. This amendment updates a previous Schedule 13G, signifying a passive investment.
[SCHEDULE 13G/A] Inspire Medical Systems, Inc. Amended Passive Investment Disclosure
Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., and James E. Flynn filed an amended Schedule 13G/A for Inspire Medical Systems, Inc. The filing indicates that as of March 31, 2026, the Reporting Persons beneficially owned 2,703,238 shares (9.38% of class) but as of May 14, 2026, they ceased to beneficially own more than 5.0% of the outstanding ordinary shares, with current beneficial ownership reported at 1,296,862 shares (4.50% of class). This amendment reflects a change in their passive investment status, specifically dropping below the 5% ownership threshold.
INSP (NYSE) Form 144: Director/Holder Notices Sale of 700 Shares via Morgan Stanley
A Form 144 filing indicates a proposed sale of 700 shares of Inspire Medical Systems, Inc. (INSP) common stock, resulting from restricted stock vesting on February 20, 2026. Morgan Stanley Smith Barney LLC is listed as the broker for this potential transaction, which will trade on the NYSE. The filing is a notice of intent to sell, not a completed sale, with actual transaction details to be reported later if the sale occurs.
Inspire Medical Systems (INSP) price target decreased by 17.14% to 72.73
The article reports that the price target for Inspire Medical Systems (INSP) has been decreased by 17.14% to $72.73. This indicates a significant downward revision in the expected valuation of the company's stock by analysts.
A Look At Inspire Medical Systems (INSP) Valuation After Forecast Downgrades And Guidance Reset
Inspire Medical Systems (INSP) has seen its stock price drop following analyst downgrades, a shift from profit to net loss, and reduced 2026 guidance. While the stock is significantly down over the past year, Simply Wall St's narrative suggests it could be 44.5% undervalued, positing that current issues with the Inspire V system rollout are temporary. Investors are urged to perform their own due diligence, considering both risks and potential rewards highlighted by the analysis.
A Look At Inspire Medical Systems (INSP) Valuation After Forecast Downgrades And Guidance Reset
Inspire Medical Systems (INSP) has seen its forecasts downgraded and guidance reset after a Q1 net loss and weaker trading, with shares down significantly. Despite this, analysts peg its fair value at $79.42, suggesting it's currently undervalued by 44.5% due to expected resolution of temporary issues and reacceleration of growth. Investors are advised to review the data to assess the risks and potential rewards.
Inspire Medical Systems stock hits 52-week low at $43.01
Inspire Medical Systems (INSP) stock has dropped to a new 52-week low of $43.01, representing a 73% decrease over the past year. Despite strong Q1 2026 earnings, the company revised its full-year sales guidance downward by 4% to 10%, leading to reduced price targets from analysts. InvestingPro data suggests the stock might be undervalued despite these challenges, with expectations of profitability this year.
INSP Technical Analysis | Trend, Signals & Chart Patterns | INSPIRE MEDICAL SYSTEMS INC (NYSE:INSP)
This article provides a technical analysis of INSPIRE MEDICAL SYSTEMS INC (NYSE:INSP), assigning it a poor overall technical rating of 0 out of 10. The stock shows negative trends in both the short and long term, performs poorly compared to the overall market and its industry peers, and is currently trading near a new 52-week low. Various technical indicators like RSI, MACD, and SMA confirm a bearish outlook, suggesting it's better to avoid buying the stock for now.
Director at Inspire Medical (NYSE: INSP) sells 696 company shares
Inspire Medical director Shawn McCormick sold 696 shares of Common Stock at $45.31 each in an open-market transaction, as reported in a Form 4 SEC filing. After the sale, McCormick directly holds 27,712 shares, with an additional 3,000 shares held indirectly by trust. This transaction was made pursuant to a Rule 10b5-1 trading plan dated August 29, 2025.
Inspire Medical Systems director Shawn McCormick sells $31,535 stock
Inspire Medical Systems director Shawn McCormick sold 696 shares of company stock for $31,535 on May 8, 2026, pursuant to a Rule 10b5-1 trading plan. This transaction occurred amidst a stock decline to near its 52-week low, despite positive Q1 2026 earnings. The company faces mixed sentiment due to revised negative sales growth guidance, leading several analysts to lower price targets and one to downgrade their rating.
5 Insightful Analyst Questions From Inspire Medical Systems’s Q1 Earnings Call
Inspire Medical Systems faced a negative market response after its Q1 earnings, with management citing persistent challenges in reimbursement coding and operational disruptions from the WISER program. The company revised its full-year revenue guidance downward to $825 million to $875 million and adjusted EPS guidance to $0.75 to $1.25. Analysts' questions focused on the assumptions behind the revised guidance, potential for pent-up demand, the impact of GLP-1 medications, salesforce realignment, and clarity on WISER state procedural backlogs.
5 Insightful Analyst Questions From Inspire Medical Systems’s Q1 Earnings Call
Inspire Medical Systems faced a negative market response after its Q1 earnings, largely due to persistent challenges in reimbursement coding and operational disruptions from the WISER program, leading to a significant downward revision of its full-year guidance for both revenue and adjusted EPS. Analysts focused on understanding the assumptions behind the revised guidance, the impact of reimbursement issues, and how the company plans to navigate these challenges. Key areas to monitor include improvements in coding comfort, reduction in procedural delays, and the outcome of new clinical data.
Inspire Medical Systems (INSP) Is Down 18.8% After Cutting 2026 Outlook And Filing Share Offering – Has The Bull Case Changed?
Inspire Medical Systems (INSP) recently reported a Q1 2026 net loss and cut its 2026 revenue outlook to US$825-US$875 million, a decline from 2025, due to coding and reimbursement uncertainty. This revision follows a US$118.82 million share offering and has led to an 18.8% stock price drop, challenging the prior investment narrative which projected significant growth. The company's future hinges on resolving reimbursement issues for its Inspire V therapy.
Inspire Medical Systems (INSP) Is Down 18.8% After Cutting 2026 Outlook And Filing Share Offering – Has The Bull Case Changed?
Inspire Medical Systems (INSP) experienced an 18.8% stock drop after reporting a first-quarter net loss and cutting its 2026 revenue outlook to between US$825 million and US$875 million, a 4% to 10% decline from 2025. The company also filed a US$118.82 million shelf registration. This negative performance is largely attributed to ongoing uncertainty surrounding coding and reimbursement for its OSA therapy, particularly for its Inspire V product, which directly impacts its growth potential and valuation.
Inspire Medical Systems (INSP) Is Down 18.8% After Cutting 2026 Guidance Amid Reimbursement Challenges - What's Changed
Inspire Medical Systems reported Q1 2026 results with reduced 2026 revenue and EPS guidance due to reimbursement and coding challenges. The company also filed a shelf registration for common shares and gained shareholder approval for an expanded incentive plan, signaling an emphasis on workforce and governance amidst these headwinds. This situation has led to an 18.8% drop in its stock price, prompting a reevaluation of its investment narrative given the potential for lingering reimbursement issues.
[144] Inspire Medical Systems, Inc. SEC Filing
This article details an SEC Form 144 filing by Inspire Medical Systems, Inc. on May 8, 2026. The filing indicates a proposed sale of 696 shares of common stock with an aggregate market value of $31,716.72 by an unnamed account holder, acquired on May 1, 2026, as restricted stock units from the Issuer. The transaction is being handled by Morgan Stanley Smith Barney LLC.
INSP SEC Filings - Inspire Medical 10-K, 10-Q, 8-K Forms
This page provides access to U.S. Securities and Exchange Commission filings for Inspire Medical Systems, Inc. (NYSE: INSP), including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms. It offers detailed insights into the company's financial results, risks, and corporate developments, with AI-powered summaries highlighting key points from lengthy documents. Recent filings cover topics such as beneficial ownership reports, insider sales, CFO transitions, option exercises, and board-authorized stock buybacks.
Top Inspire Medical Systems (INSP) Competitors 2026
This article identifies the top competitors for Inspire Medical Systems (INSP) in 2026: Bausch + Lomb (BLCO), Stevanato Group (STVN), Envista (NVST), iRhythm Technologies (IRTC), and TransMedics Group (TMDX). It provides a detailed comparison of INSP against each competitor across various financial metrics, profitability, media sentiment, analyst ratings, and institutional ownership. The analysis helps investors understand INSP's position relative to its peers in the medical equipment industry.
Inspire Medical Systems (INSP) Is Down 18.8% After Cutting 2026 Outlook And Filing Share Offering – Has The Bull Case Changed?
Inspire Medical Systems (INSP) shares dropped 18.8% after the company reported a first-quarter net loss, cut its 2026 revenue outlook to US$825 million to US$875 million, and filed for a US$118.82 million share offering. The revised outlook, which implies a 4% to 10% decline from 2025, is largely due to ongoing coding and reimbursement uncertainty for its Inspire V product. Investors are now scrutinizing how quickly these reimbursement issues can be resolved and if earnings can stabilize, as these factors are critical to the company's future growth and valuation.
INSP Maintained by Oppenheimer -- Rating Remains at Perform
Oppenheimer has maintained its 'Perform' rating on Inspire Medical Systems (INSP) as of May 7, 2026. Despite this cautious stance and recent price target adjustments from other firms, GuruFocus indicates that INSP is significantly undervalued with a GF Value™ of $241.35 against a current price of $45.57. The company exhibits strong financial health and growth potential but faces challenges in valuation and momentum.
Inspire Medical Systems (NYSE:INSP) - Stock Analysis
Inspire Medical Systems (NYSE:INSP) is a medical technology company focused on solutions for obstructive sleep apnea. The company faces significant challenges, including revenue and earnings forecast declines, increased competition, and reimbursement uncertainties for its new Inspire 5 system, leading to revised guidance and a substantial stock price drop. Despite exceeding Q1 2026 earnings estimates, the stock has fallen due to cautious outlooks from analysts and the company's own lowered full-year revenue guidance.
Inspire Medical Systems Inc (INSP) Stock News & Articles
Inspire Medical Systems Inc (INSP) specializes in innovative solutions for obstructive sleep apnea (OSA) with its flagship neurostimulation device. The company, based in Golden Valley, Minnesota, offers a minimally invasive treatment designed to keep airways open during sleep. An article from May 5, 2026, shares analyst calls for various companies, including Inspire Medical Systems.
Inspire Medical Systems (INSP) to report earnings tomorrow: Here is what to expect
The article indicates that Inspire Medical Systems (INSP) is scheduled to report its earnings tomorrow. It suggests that investors should be aware of the key factors that could influence the upcoming earnings report. The piece aims to provide insights into what to expect from the company's financial results.
Assessing Inspire Medical Systems (INSP) Valuation After Prolonged Share Price Weakness
Inspire Medical Systems (INSP) has experienced significant share price declines, including a 70.19% drop over the past year. Despite this, Simply Wall St's analysis suggests the company might be undervalued at its current price of $48.25, with a narrative fair value of $79.42, due to expected reacceleration in procedure volumes and revenue growth in 2026 as transitory issues resolve. The article encourages investors to verify the bullish and cautious points independently and explore other investment opportunities.
Investors back new equity plan and board changes at Inspire Medical (NYSE: INSP)
Inspire Medical Systems, Inc. announced that stockholders approved an amended equity plan, adding 2.6 million shares and instituting stricter vesting and dividend rules. Investors also approved a change to phase out the classified board structure, moving to annual director elections by 2029. All proposals, including director elections and auditor ratification, received sufficient support at the annual meeting where approximately 88% of outstanding common stock was represented.
Inspire Medical Systems (INSP) Stock Trades Down, Here Is Why
Inspire Medical Systems (INSP) shares dropped 16% after the company significantly lowered its full-year 2026 revenue and earnings guidance due to ongoing reimbursement and coding challenges. This negative outlook overshadowed first-quarter results that surpassed Wall Street expectations. The stock has been highly volatile, with a 50.3% decline year-to-date and a 71.7% drop from its 52-week high in May 2025.
Inspire Medical Systems (INSP) Stock Trades Down, Here Is Why
Inspire Medical Systems (INSP) shares fell 16% after the company lowered its full-year 2026 revenue and earnings guidance, citing persistent reimbursement and coding challenges. This overshadowed better-than-expected first-quarter results. The stock has been volatile, with a significant drop earlier due to similar guidance cuts and is currently trading significantly below its 52-week high.
Mizuho cuts Inspire Medical Systems stock price target on guidance reduction
Mizuho has reduced its price target for Inspire Medical Systems (NYSE:INSP) shares from $70 to $55, while maintaining an Outperform rating. This adjustment follows Inspire Medical's significant guidance cut for 2026, with expected sales growth now projected to be negative 4% to negative 10%, a steep decline from earlier forecasts. The company cited utilization headwinds from coding confusion and the impact of WISeR programs and GLP-1 as reasons for the revised outlook.
Piper Sandler Downgrades Inspire Medical Systems to Neutral From Overweight, $85 Price Target
Piper Sandler has downgraded Inspire Medical Systems (INSP) from an Overweight rating to Neutral, setting an $85 price target. This rating change was reported by MT Newswires, alongside a mention of Unity Software's recent Q4 earnings report which showed a revenue increase of 35% year-over-year to $609 million. The news highlights significant financial movements for companies in the investment market.
Inspire Medical Systems stock hits 52-week low at $45.00
Inspire Medical Systems stock has dropped to a 52-week low of $45.00, reflecting a significant decline in market performance despite exceeding Q1 2026 earnings expectations. Analyst firms like Mizuho and BofA Securities have lowered price targets and ratings due to concerns over future guidance, reimbursement challenges, and increased competition. InvestingPro analysis suggests the stock may be undervalued given the company's strong balance sheet.
Inspire Medical Systems, Inc. (NYSE:INSP) Q1 2026 Earnings Call Transcript
Inspire Medical Systems, Inc. (INSP) reported Q1 2026 earnings, beating expectations with an EPS of $0.10. However, the company is revising its full-year revenue outlook to $825 million to $875 million due to significant challenges from coding and reimbursement uncertainty, and the WISER program, which are estimated to impact revenue by $120 million to $150 million. Despite these headwinds, Inspire is focusing on disciplined spending, targeted investments for growth, and supporting customers through education and assistance with billing processes, while also highlighting positive clinical data for its Inspire V system.
Truist Securities Adjusts Price Target on Inspire Medical Systems to $50 From $64, Maintains Hold Rating
Truist Securities has adjusted its price target for Inspire Medical Systems (INSP) to $50 from the previous $64, while maintaining a Hold rating on the stock. This adjustment comes amidst other analyst actions, including RBC cutting its price target to $45 and both Piper Sandler and BofA Securities downgrading the stock to Neutral. The company also recently reported its Q1 2026 earnings, with adjusted earnings flat and revenue rising, but lowered its full-year guidance for 2026.
Mizuho cuts Inspire Medical Systems stock price target on guidance reduction
Mizuho has lowered its price target for Inspire Medical Systems (INSP) shares to $55 from $70, while maintaining an Outperform rating. This reduction follows a significant guidance cut by the company for 2026, which now anticipates negative sales growth. Despite the revised outlook and current market sentiment, InvestingPro analysis suggests the stock is undervalued, and the company recently reported strong Q1 2026 earnings that exceeded analyst expectations.
Inspire Medical Systems (INSP) Q1 earnings and revenues top estimates
This article reports that Inspire Medical Systems (INSP) exceeded Q1 earnings and revenue estimates. The financial performance of the company for the first quarter included revenues and earnings that surpassed analyst expectations.
Inspire Medical Systems, Inc. Announces First Quarter 2026 Financial Results and Updates 2026 Guidance
Inspire Medical Systems, Inc. reported a 1.6% revenue growth in Q1 2026, reaching $204.6 million, with a diluted EPS of $(0.39) and adjusted diluted EPS of $0.10. The company faced challenges from coding and reimbursement uncertainty and the WISeR program but maintained focus on revenue-generating activities and cost management. Inspire Medical Systems updated its full-year 2026 guidance, projecting revenue between $825 million and $875 million, representing a decline of 4% to 10% compared to 2025, and expects revenue growth to return in 2027.
[10-Q] Inspire Medical Systems, Inc. Quarterly Earnings Report
Inspire Medical Systems, Inc. (INSP) has filed its quarterly earnings report (10-Q) for the period ending March 31, 2026. The company reported a net loss of $11.294 million, compared to net earnings of $2.992 million in the prior-year period. Revenue increased slightly to $204.583 million, but was impacted by uncertainty surrounding coding and reimbursement for its Inspire V neurostimulator and the Wasteful and Inappropriate Service Reduction (WISeR) program, as well as the increasing prevalence of GLP-1 drugs for obstructive sleep apnea.
Inspire Medical Systems (INSP) director receives 3,562 RSUs in equity grant
Inspire Medical Systems director Shawn McCormick was granted 3,562 Restricted Stock Units (RSUs) at no cash cost, increasing his direct holdings to 28,408 shares. These RSUs will vest on the first anniversary of the grant date or immediately before a Change of Control, provided he continues his service to the company. Additionally, 3,000 shares are held indirectly through a trust.
Inspire Medical (INSP) director receives 3,562-share RSU award
Casey M. Tansey, a director at Inspire Medical Systems (INSP), was granted 3,562 Restricted Stock Units (RSUs) as a stock-based compensation award. These RSUs, which represent a contingent right to receive one share of common stock each, vest based on continued service. Following this grant, Tansey directly holds 26,286 shares of common stock, with additional indirect holdings through family trusts.
